United States: Capitol Hill Healthcare Update

CHIP Renewal Triggers Partisan Clash Over Offsets

Although the Children's Health Insurance Program (CHIP) enjoys broad bipartisan support on Capitol Hill, lawmakers last week sharply disagreed over how to pay for its renewal – signaling that a final vote could be delayed for months.

The House Energy and Commerce Committee and the Senate Finance Committee last week approved separate versions of bills to renew federal CHIP funding. The Senate process has so far been bipartisan though committee Chairman Orrin Hatch (R-Utah) and the panel's top Democrat, Sen. Ron Wyden (D-Ore.) have not spelled out how they would pay for their bill.

The House's CHIP bill won committee approval on a party-line vote as Democrats balked at most of the Republicans' proposed offsets, including one that would tap the Affordable Care Act's (ACA's) prevention fund. Other GOP-backed offsets included requiring Americans with incomes above $500,000 to pay higher Medicare premiums and effectively banning lottery winners from being eligible for Medicaid.

Federal CHIP funding expired September 30 though states have funding to administer the program through December.

Ryan Hints at Medicaid Reform Effort in 2018

Speaker Paul Ryan last week said the House is unlikely to consider any new legislative effort to repeal or replace the ACA, but is targeting sweeping Medicaid reform next year.

Ryan said the House would only debate new ACA legislation if there is a clear indication it could pass the Senate, which has twice flubbed efforts to repeal the law this year.

The Speaker said in 2018 he wanted to push welfare and Medicaid reforms, including either block grants or per-capita caps that he said enjoy widespread support among House Republicans. Ryan said Republicans intend to use fast-track legislation known as reconciliation for Medicaid changes. A reconciliation bill can win Senate approval on a party-line vote, not the usual 60 votes needed for passage.

Some Republicans Unconcerned by Trump's Outreach to Democrats

Some congressional Republicans reacted with shrugged shoulders to reports that President Trump last week called Senate Democratic Leader Chuck Schumer (D-N.Y.) to discuss a potential bipartisan agreement on healthcare.

While there was some concern about Trump's unilateral outreach to Schumer, other Republicans saw the effort as an attempt to prod the GOP on healthcare – and as Trump trying to separate himself from Congress' inability to repeal the ACA.

Last month, the president did work with Schumer and House Democratic Leader Nancy Pelosi (D-Calif.) on a stopgap budget plan that delayed a partisan showdown on government funding and the debt ceiling. Still, the policy and political gulfs between Trump and congressional Democrats on healthcare are far wider than what separates Republicans.

Allergan-Tribe Patent Inquiry Becomes Bipartisan

While Democrats have sharply criticized Allergan for effectively blocking federal challenges of its Restasis treatment for chronic dry eye by selling the drug's patents to a Native American tribe, a key congressional Republican last week also questioned the move.

House Oversight and Government Reform Committee Chairman Trey Gowdy (R-S.C.) said the Allergan agreement with the Saint Regis Mohawk Tribe in upstate New York could hurt competition by thwarting cheaper generic alternatives. Gowdy and the panel's top Democrat, Rep. Elijah Cummings (D-Md.), sent a letter last week to CEO Brent Saunders with a series of questions, including some seeking internal company analyses on Restasis' projected market share following the deal with the tribe.

Separately, Sen. Claire McCaskill (D-Mo.) last week introduced legislation that would block tribes from using sovereign immunity to evade federal challenges to pharmaceutical patents.

McCaskill's legislation is the latest attempt by Democrats to focus attention on Allergan. Earlier this month, four Democrats – Sens. Maggie Hassan (D-N.H.), Sherrod Brown (D-Ohio), Robert Casey (D-Pa.) and Richard Blumenthal (D-Conn.) – called on the Judiciary Committee to investigate what the senators said was Allergan's "blatantly anti-competitive" effort to skirt federal law.

Senate Panel to Hold Hearing on Drug Costs

The Senate HELP Committee on Oct. 17 will hold its second hearing this year on prescription drug costs, focusing on how the drug delivery system affects what patients pay.

Witnesses will include Lori Reilly of PhRMA and Chip Davis of the Association for Accessible Medicines, formerly GPhA. Other witnesses include Elizabeth Gallenagh of the Healthcare Distribution Alliance, Mark Merritt of the Pharmaceutical Care Management Association and Thomas Menighan of the American Pharmacists Association.

The Senate HELP Committee in June held its first hearing on drug prices, which quickly dissolved into a partisan clash over Republicans' effort to repeal the ACA. At the time, Committee Chairman Lamar Alexander (R-Tenn.) questioned the value of the hearing and speculated on whether additional hearings on drug prices would be meaningful.

Senate GOP Panel Questions HHS on Opioid Fraud

Eleven Republicans on the Senate Finance Committee last week sought information on steps the U.S. Department of Health and Human Services (HHS) is taking to prevent opioid abuse by Medicare Part D providers and beneficiaries.

A report last summer by HHS's inspector general expressed concern about the number of opioids prescribed within Part D and potential problems faced by at-risk beneficiaries as well as pharmacists and providers. The report identified 500,000 beneficiaries in the Medicare Part D program who received high amounts of opioids and more than 400 prescribers who had questionable opioid prescribing patterns.

In a letter to HHS Acting Secretary Don Wright, the senators asked what the department is doing to investigate those 400 prescribers and whether HHS is considering additional safeguards to ensure Medicare does not reimburse for opioids that are being abused or diverted.

Committee Chairman Orrin Hatch (R-Utah) led the letter.

Senate Confirms HHS Deputy Who Will Serve as Acting Secretary

The Senate last week confirmed Eric Hargan to fill the No. 2 position at HHS, but because of former Secretary Tom Price's resignation Hargan will serve as the department's acting secretary for at least several months.

Hargan won Senate confirmation 57-38, picking up support from eight Senate Democrats, though some Democrats sharply criticized Hargan as unlikely to deviate from Price's efforts to dismantle the ACA via department regulations.

He previously served at HHS during the Bush administration, including as deputy general counsel. Hargan, who was part of President Trump's HHS transition team last year, will fill the top job at HHS until Trump chooses and the Senate confirms Price's successor.

House, Senate Move in IPAB Repeal

Few portions of the ACA are as legitimate bipartisan targets for repeal as the controversial Independent Payment Advisory Board (IPAB), and House and Senate Republicans last week took steps to repeal the Medicare cost-cutting panel.

House lawmakers are working to include IPAB repeal in legislation to renew CHIP. Meanwhile, the Senate Budget Committee last week approved an amendment to the fiscal 2018 budget resolution that would allow for IPAB repeal.

Created in 2010 as a cost-containment tool, IPAB has virtually limitless power to change Medicare spending, which worries not only conservative Republicans but also liberal Democrats. Stand-alone IPAB repeal legislation in the House has 264 co-sponsors, including 43 Democrats – though many more Democrats have expressed reservations about the board.

Although currently dormant, IPAB would spring to life if Medicare spending exceeded certain thresholds. IPAB could propose wholesale changes to Medicare reimbursement that could only be blocked by votes of super-majorities in Congress, and lawmakers say IPAB effectively usurps congressional authority to make changes to Medicare.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions